

Nomogram for Predicting Early AVF Failure in Elderly Diabetic Patients: Methodological and Clinical Considerations [Letter]

Shi-Cheng Liu¹, Kun Tian¹, Yu-Ting Zhang²

¹Department of Vascular Surgery, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; ²Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China

Correspondence: Yu-Ting Zhang, Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, West Lake Road 38, Hangzhou, 310009, People's Republic of China, Email zhangyuting0916@sina.com

Dear editor

As physicians specializing in vascular surgery, we have reviewed a recent article focusing on the development of a nomogram to predict early failure of arteriovenous fistulas (AVFs) in elderly diabetic patients.¹ The article presents some innovative methodologies and results; however, several aspects, including methodology and clinical applicability, warrant further discussion.

Data Collection and Sample Selection

Firstly, regarding data collection and sample selection, while the sample size of 548 patients is considerable, it remains relatively limited when compared to the vast global population of elderly patients with diabetes and end-stage renal disease (ESRD). More importantly, the study includes cases from a single center, which may limit the generalizability of the findings across different regions and healthcare settings. Although the exclusion criteria help control variables, they may also exclude clinically challenging cases, thereby affecting the model's predictive ability in complex clinical environments. For instance, patients with severe co-morbidities, advanced age, or a history of multiple failed AVF attempts are often among the most challenging to treat and may be underrepresented in this study. This could affect the model's predictive ability in these complex clinical environments, where accurate risk assessment and tailored interventions are most crucial. Furthermore, the article does not explicitly address the handling of missing data, a common issue in medical research that, if not managed properly, can lead to biased results.²

Internal Validation and External Validation

Secondly, internal validation was performed using the bootstrap method with 1000 resamples, yielding promising results with an AUC of 0.912. While the bootstrap method is robust, it relies heavily on the original dataset and may not fully capture the variability and complexity of real-world clinical scenarios. Crucially, internal validation cannot substitute for external validation, which entails testing the model on a fully independent dataset, preferably from a different geographical location, time period, or patient subgroup.³ This is vital because patient populations can vary considerably in demographics, comorbidities, and treatment strategies. Regrettably, the predictive nomogram developed by Liu et al lacked external validation, a limitation that future research should strive to rectify.

Clinical Applicability and Limitations

Thirdly, regarding clinical applicability and limitations, the nomogram model comprising five variables, although relatively easy to obtain in clinical practice, poses challenges when integrating them into a user-friendly predictive

tool. Non-vascular surgery specialists may find it difficult to understand and apply this model. Although the model's predictive performance is good in both training and validation datasets, it does not discuss differences among various patient subgroups (eg, gender, age, duration of diabetes). Furthermore, the model does not consider non-biological factors affecting AVF maturation, such as surgical technique and postoperative care.⁴ Ethical and cost-effectiveness considerations, including balancing costs and benefits of preventive measures for high-risk patients, have not been addressed in the model's clinical application.

Suggestions

We suggest expanding the sample size and incorporating multi-center data to enhance the model's representativeness and generalization ability. Advanced statistical methods, such as Bayesian networks or random forests, can be explored for variable selection and model construction, followed by rigorous external validation to assess the model's true performance.⁵ Prospective studies should be conducted to evaluate the model's application in clinical decision-making and explore its integration with existing healthcare processes to improve patient care quality. Future research can address these limitations and provide a more reliable and practical predictive tool for clinical use.

Disclosure

The authors declare no conflicts of interest in this communication.

References

1. Liu S, Wang Y, He X, Li X. Construction and evaluation of a predictive nomogram for identifying premature failure of arteriovenous fistulas in elderly diabetic patients. *Diabetes Metab Syndr Obes.* 2024;17:4825–4841. doi:10.2147/DMSO.S484041
2. Austin PC, White IR, Lee DS, van Buuren S. Missing data in clinical research: a tutorial on multiple imputation. *Can J Cardiol.* 2021;37(9):1322–1331. doi:10.1016/j.cjca.2020.11.010
3. Chen TL, Buddhiraju A, Seo HH, Subih MA, Tuchinda P, Kwon YM. Internal and external validation of the generalizability of machine learning algorithms in predicting non-home discharge disposition following primary total knee joint arthroplasty. *J Arthroplasty.* 2023;38(10):1973–1981. doi:10.1016/j.arth.2023.01.065
4. Zhang J, Fan Y, Luo X, et al. Construction and validation of a prediction model for arteriovenous fistula thrombosis in patients with AVF using Lasso regression. *J Vasc Access.* 2025. doi:10.1177/11297298241301130
5. Dobashi N, Saito S, Nakahara Y, Matsushima T. Meta-tree random forest: probabilistic data-generative model and Bayes optimal prediction. *Entropy.* 2021;23(6):768. doi:10.3390/e23060768

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Diabetes, Metabolic Syndrome and Obesity

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>

Dovepress
Taylor & Francis Group